Embed Size (px)
Citation preview
Global Molecular Diagnostics Market & Future Forecast 2010 ‐ 2014
Renub Researchwww.renub.com
Publisher: Renub ResearchPublished: July, 2011
© Renub Research Page 2 of 27
Global Molecular Diagnostics - Market Overview
The global molecular diagnostics market is witnessing a period of profound growth. The
growth is coming from different regions and markets. The various application and
technological sub-segments of molecular diagnostics are also giving the market a big push.
The increase in the aging population and incidences of various chronic diseases are driving the
demand of molecular diagnostics world over. The industry is getting a push from every side
and many factors collectively are fuelling the growth in this industry.
Molecular diagnostics is a vital and dynamic field in which yesterday’s new technologies and
platforms are today becoming populated with novel, diverse, and useful content. Growing
with a CAGR of 19 percent global molecular diagnostics market is expected to reach US$ 15
Billion by 2014.The fastest growing segment is infectious disease with 21% market share as the
dominant segment. The next fastest growing segment is oncology testing due to rising cases of
cancer patients .The future growth is expected to come from genetic testing, blood screening
testing and neurological testing.
Geographically, the US and EMEA markets are the most advanced in terms of adoption of
molecular testing and make up the majority of the existing market. However, Japanese
molecular diagnostics market is promising with the ageing population and a declining birth
rate is putting the whole Japanese healthcare system under pressure. Under such
circumstances, the role of preventive medical care is increasingly important. China and India
molecular diagnostics market is one of the lucrative markets to rollout the diagnosis business.
As with the rapid advancement Chinese and Indian economy has dramatically increased the
purchasing power of a growing segment of the populace, which coupled with an emerging
mindset toward wellness, preventive medicine, and access to cutting-edge products and
services and makes the future outlook extremely positive for this very exciting new field in
clinical care. The provision of new and cutting-edge molecular tests will surely be followed by
greater affordability as prices come down due to return on investment, competition, and
technology advancement.
© Renub Research Page 3 of 27
Report Details
“Global Molecular Diagnostics Market & Future Forecast 2010 - 2014” report published by
Renub Research provides an in-depth analysis of the past, present and future prospects. The
report has been researched at source globally and features latest available data covering:
• Global Molecular Diagnostics Market (2008 to 2014)
• Top 8 application wise molecular diagnostics (Infectious Disease Testing, Blood
Screening Testing, Oncology Testing, Genetic Testing, Tissue Typing Testing,
Cardiovascular Disease Testing, Neurological Testing and Food Pathogen Detection
Testing) data of Past, Present and Future Market (2008 to 2014)
• Top 7 technological wise molecular diagnostics (PCR based tests, PCR related
technologies, Non-PCR tests, FISH & Innovation testing, Biochips, Biosensor & Other
technologies) data of Past, Present and Future Market (2008 to 2014)
• Top 9 Countries (USA, Europe the Middle East & Africa , Japan, China, India, Germany,
Brazil, Mexico and South Korea) data of Past, Present and Future Market
• Mergers and Acquisitions in the molecular diagnostics market
• Key drivers of growth in the molecular diagnostics market
• Key Players in the molecular diagnostics market
Research Highlights
• Globally, Molecular Diagnostics market is expected to reach US$ 15 Billion by 2014
• Infectious disease testing dominates the molecular diagnostics market with more than
21% market share in 2010
• Oncology and infectious disease testing sectors are likely growth leaders in the
molecular diagnostics market
• Blood Screening & Genetic testing will have a combined market share of 26% by 2014
• Biochips market is expected to cross US$ 3 Billion by 2014
• Fish & Innovation testing is expected to capture more than 16% market share by 2014
• USA is expected to have more than US$ 6 Billion molecular diagnostics market by 2014
© Renub Research Page 4 of 27
Key Players Analyzed
This section covers the key facts about the major players in molecular diagnostics market.
The key players analyzed in this section are Roche, Abbott, Bayer AG, Qiagen, Gen-Probe,
Becton Dickinson and Company, bioMérieux, Myriad Genetics, Inc., Celera Corporation.
Data Sources
Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.
© Renub Research Page 5 of 27
About Us
RReennuubb RReesseeaarrcchh is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have long-term experience especially in
international Business-to-Business Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information
Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services
(Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG,
Consumer Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.
For more information on us or to view any of our sample work you can
mail us at [email protected]
© Renub Research Page 6 of 27
Published
By
RReennuubb RReesseeaarrcchh A–116B, Sector–27
Noida – 201301
Phone: +91-120-4219-822, 2545-750 (India)
+1-678-3020-700 (USA)
Fax : +91-120-4249-780
Email: [email protected]
www.renub.com
© Global Molecular Diagnostics Market & Future Forecast 2010 - 2014
Renub Research, 2011
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers
© Renub Research Page 7 of 27
Table of Contents
1. Executive Summary
2. Global – Molecular Diagnostics Market & Market Shares (Application wise and Technological wise)
2.1 Molecular Diagnostics Market & Future Forecast
2.2 Molecular Diagnostics Market Share & Future Forecast (Application Segment)
2.3 Molecular Diagnostics Market Share & Future Forecast (Technologies Segment)
3. Molecular Diagnostics Market (Application Segment) – 2008 to 2014
3.1 Infectious Disease Testing Market
3.1.1 Virology Testing Market
3.1.2 Haemagglutination-Inhibition Test (HAI) Testing
3.1.3 Critical Care Infectious Testing Market
3.2 Blood Screening Market
3.3 Genetic Testing Market
3.4 Oncology Testing Market
3.5 Tissue Typing (HLA Testing) Market
3.6 Cardiovascular Disease Testing Market
3.7 Neurological Disorders Testing Market
3.8 Food Pathogen Detection Testing Market
4. Molecular Diagnostics Market (Technologies Segment) – 2008 to 2014
4.1 PCR Based Test Market
4.2 PCR Related Technologies Market
4.3 Non-PCR Test Market
4.4 Fish & Innovations Testing Market (Fluorescent in-situ hybridization)
4.5 Biochips Market
4.6 Biosensors
4.7 Other Technologies Market
5. Geographical Distribution - Molecular Diagnostics Market (2008 to 2014)
© Renub Research Page 8 of 27
5.1 United States Molecular Diagnostics Market
5.2 Europe, the Middle East & Africa (EMEA) Molecular Diagnostics Market
5.3 Germany Molecular Diagnostics Market
5.4 India Molecular Diagnostics Market
5.5 China Molecular Diagnostics Market
5.6 Japan Molecular Diagnostics Market
5.7 Brazil Molecular Diagnostics Market
5.8 Mexico Molecular Diagnostics Market
5.9 South Korea Molecular Diagnostics Market
6. Global Mergers & Acquisitions Deals in the Molecular Diagnostics Sector
7. Key Drivers of Growth in Global Molecular Diagnostics Market
7.1 Aging of the population
7.2 Re-Emergence of infectious threats (drug resistant TB, new strains of HIV, H1N1 & other flu)
7.3 Scientific and Technological Advancements
8. Challenges
8.1 Reimbursement
8.2 The need for new Biomarker Assays
8.3 Regulatory Environment
8.4 Awareness and Acceptance
9. Key Players
9.1 Roche
9.2 Abbott Laboratories
9.3 Qiagen
9.4 BD (Becton, Dickinson and Company)
9.5 biomerieux
9.6 Bayer AG
9.7 Gen-Probe
9.8 Myriad Genetics, Inc
© Renub Research Page 9 of 27
9.9 Celera Corporation
9.10 Beckman Coulter
© Renub Research Page 10 of 27
List of Figures:
Figure 2-1: Global - Molecular Diagnostics Market (Million US$), 2008 - 2010
Figure 2-2: Global - Forecast for Molecular Diagnostics Market (Million US$), 2011- 2014
Figure 2-3: Global - Segments of Molecular Diagnostics Market Share (Percent), 2008 - 2010
Figure 2-4: Global - Forecast for Segments of Molecular Diagnostics Market Share (Percent), 2011 - 2014
Figure 2-5: Global - Molecular Diagnostics Market Share Technologies wise (Percent), 2008 - 2010
Figure 2-6: Global - Forecast for Molecular Diagnostics Market Share Technologies wise (Percent), 2011
- 2014
Figure 3-1: Global - Infectious Disease Testing Market (Million US$), 2008 - 2010
Figure 3-2: Global - Forecast for Infectious Disease Testing Market (Million US$), 2011 - 2014
Figure 3-3: Global - Virology Testing Market (Million US$), 2007 - 2010
Figure 3-4: Global - Forecast for Virology Testing Market (Million US$), 2011 - 2014
Figure 3-5: Global - HAI Testing Market (Million US$), 2008 - 2010
Figure 3-6: Global - Forecast for HAI Testing Market (Million US$), 2011 - 2014
Figure 3-7: Global - Critical Care Infectious Testing Market (Million US$), 2008 - 2010
Figure 3-8: Global - Forecast for Critical Care Infectious Testing Market (Million US$), 2011 - 2014
Figure 3-9: Global - Blood Screening Market (Million US$), 2007 - 2010
Figure 3-10: Global - Forecast for Blood Screening Market (Million US$), 2011 - 2014
Figure 3-11: Global - Genetic Testing Market (Million US$), 2007 - 2010
Figure 3-12: Global - Forecast for Genetic Testing Market (Million US$), 2011 - 2014
Figure 3-13: Global - Oncology Market (Million US$), 2007 - 2010
Figure 3-14: Global - Forecast for Oncology Market (Million US$), 2011 - 2014
Figure 3-15: Global - Tissue Typing Market (Million US$), 2008 - 2010
Figure 3-16: Global - Forecast for Tissue Typing Market (Million US$), 2011 - 2014
Figure 3-17: Global - Cardiovascular Disease Testing Market (Million US$), 2005 - 2010
Figure 3-18: Global - Forecast for Cardiovascular Disease Testing Market (Million US$), 2011 - 2014
Figure 3-19: Global - Neurological Disorders Testing Market (Million US$), 2005 - 2010
Figure 3-20: Global - Forecast for Neurological Disorders Testing Market (Million US$), 2011 - 2014
Figure 3-21: Global - Food Pathogen Detection Testing Market (Million US$), 2005 - 2010
Figure 3-22: Global - Forecast for Food Pathogen Detection Testing Market (Million US$), 2011 - 2014
Figure 4-1: Global - PCR Based Test Market (Million US$), 2005 - 2010
Figure 4-2: Global - Forecast for PCR Based Test Market (Million US$), 2011 - 2014
Figure 4-3: Global - PCR Related Technologies Market (Million US$), 2005 - 2010
Figure 4-4: Global - Forecast for PCR Related Technologies Market (Million US$), 2011 - 2014
Figure 4-5: Global - Non-PCR Test Market (Million US$), 2005 - 2010
Figure 4-6: Global - Non-PCR Test Market (Million US$), 2011 - 2014
© Renub Research Page 11 of 27
Figure 4-7: Global - Fish & Innovations Market (Million US$), 2005 - 2010
Figure 4-8: Global - Forecast for Fish & Innovations Market (Million US$), 2011 - 2014
Figure 4-9: Global - Biochips/ Microarrays Market (Million US$), 2005 - 2010
Figure 4-10: Global - Forecast for Biochips/Micrroarrays Market (Million US$), 2011 - 2014
Figure 4-11: Global - Biosensors Market (Million US$), 2005 - 2010
Figure 4-12: Global - Forecast for Biosensors Market (Million US$), 2011 - 2014
Figure 4-13: Global - Other Technologies Market (Million US$), 2005 - 2010
Figure 4-14: Global - Forecast for Other Technologies Market (Million US$), 2011 - 2014
Figure 5-1: US - Molecular Diagnostics Market (Million US$), 2002 - 2010
Figure 5-2: US - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-3: EMEA - Molecular Diagnostics Market (Million US$), 2007 - 2010
Figure 5-4: EMEA - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-5: Germany - Molecular Diagnostics Market (Million US$), 2009 - 2010
Figure 5-6: Germany - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-7: India - Molecular Diagnostics Market (Million INR), 2006 - 2010
Figure 5-8: India - Forecast for Molecular Diagnostics Market (Million INR), 2011 - 2014
Figure 5-9: China - Molecular Diagnostics Market (Million US$), 2004, 2007 - 2010
Figure 5-10: China - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-11: Japan - Molecular Diagnostics Market (Million US$), 2007 - 2010
Figure 5-12: Japan - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-13: Brazil - Molecular Diagnostics Market (Million US$), 2007 - 2010
Figure 5-14: Brazil - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-15: Mexico - Molecular Diagnostics Market (Million US$), 2007 - 2010
Figure 5-16: Mexico - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 5-17: South Korea - Molecular Diagnostics Market (Million US$), 2005 - 2010
Figure 5-18: South Korea - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Figure 7-1: Global - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009,
2025 & 2050
Figure 7-2: Old-age Dependency Ratio: Major Areas, 2009 & 2050
© Renub Research Page 12 of 27
List of Tables:
Table 6-1: Global - Mergers & Acquisitions Deals in the Molecular Diagnostics Sector (Million US$) 2006 -
2010
Table 7-1: Global - Population Aged 60 or Over, 65 or Over and 80 Or Over By Sex (Thousands): World,
Major Areas and Regions, 2009
Table 9-1: Roche - Key Financials (Million US$) 2008 - 2010
Table 9-2: Abbott Laboratories - Key Financials (Million US$) 2008 - 2010
Table 9-3: Qiagen - Key Financials (Million US$) 2008 - 2010
Table 9-4: BD (Becton, Dickinson and Company) - Key Financials (Million US$) 2008 - 2010
Table 9-5: Biomerieux - Key Financials (Million US$) 2008 - 2010
Table 9-6: Bayer AG - Key Financials (Million US$) 2008 - 2010
Table 9-7: Gen Probe - Key Financials (Million US$) 2008 - 2010
Table 9-8: Myriad Genetics, Inc. Key Financials (Million US$) 2008 - 2010
Table 9-9: Celera Corporation - Key Financials (Million US$), 2008 - 2010
Table 9-10: Beckman Coulter - Key Financials (Million US$) 2008 - 2010
© Renub Research Page 13 of 27
2. Global – Molecular Diagnostics Market & Market
Shares (Application wise and Technological wise)
2.1 Molecular Diagnostics Market & Future Forecast
Molecular Diagnostics market is one of the fastest growing markets in the diagnostics
segment. In 2010 molecular diagnostics market was whopping US$ 7,287 Million and it is
projected to be US$ 14,864 Million by 2014. The market is expected to grow with 19.5 percent
CAGR for the period of 2010 to 2014. Molecular diagnostics will continue to grow in
importance for both the IVD community and personalized medicine, but there have been
significant structural changes in the category in the coming years.
Trends and Directions to Expect In Molecular Diagnostics
• Sector shakeout will continue as access to capital remains tight and investment needs
tighten due to an increased need to develop routes to market
• Established diagnostics and healthcare companies will acquire and tie-up assets of
promising pure play companies, especially in the areas of infectious disease and
oncology
• There will be an increased focus on novel, portable molecular diagnostics platforms to
enable the next phase of growth, ease of use and clinical value
• Pharma and biotech companies will look to take advantage of the downturn in
valuation and the potential tax-credits proposed in The Genomics and Personalized
Medicine Act of 2008
• Revenue growth will continue to favor MDx companies that also have the ability to
deliver test results as a service due to the limited options for in house capabilities or
reference labs.
© Renub Research Page 14 of 27
Figure 2-2: Global - Forecast for Molecular Diagnostics Market (Million US$), 2011- 2014
Source: Scientia Analysis, Kalorama, Frost & Sullivan, Company reports and presentations,TSG analysis, Qiagen, Roche, Hologic presentations, Renub Research Analysis
2.2 Molecular Diagnostics Market Share & Future Forecast (Application
Segment)
The molecular diagnostics industry is characterized by a very diverse, constantly changing
technology base that continuously produces new opportunities and applications. Similarly, a
growing understanding of the molecular basis of cancer and other chronic diseases is opening
up new realms of medicine to the possibilities of molecular diagnostics testing. Infectious
disease testing with 21.8% accounts for largest share in global molecular diagnostics market in
2010. Oncology testing should post strong position in the molecular diagnostics industry due
to rising cases of cancer patients that leads the market share with 22.95% by 2011 and it is
further expected to grow to 28.59% market share by 2014. The future growth in the molecular
diagnostics industry is also expected to come from genetic testing, blood screening testing
and neurological testing.
8,55010,161
12,225
14,864
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
2011 2012 2013 2014
Mill
ion
US$
© Renub Research Page 15 of 27
Figure 0-1: Global - Segments of Molecular Diagnostics Market Share (Percent), 2008 - 2010
Source: Diagnosing Diagnostics Thomas Weisel Partners, 19 March 2007, Devices and predictive diagnostics, Burill & Co.,7 May 2007, Gen Probe 28th Annual JP Morgan Healthcare Conference, 2009 estimates by Piper Jaffray (April 2010) and Gen-Probe, Scientia Analysis, Kalorama, Frost & Sullivan, Company reports and presentations, TSG analysis, Qiagen, Roche, Hologic presentations, Luminex Corporation J.P. Morgan Healthcare Conference, Gen Probe 28th Annual JP Morgan Healthcare Conference, Jain PharmaBiotech, Renub Research Analysis
2.3 Molecular Diagnostics Market Share & Future Forecast
(Technologies Segment)
Biochips and PCR based test accounts for the largest shares in the molecular diagnostics
technologies segment with 24.21% and 18.42% respectively in 2010. With the advancement of
technology, biochips has became a major thrust for the rapidly growing diagnostics industry,
which encompasses a very diverse range of research efforts including genomics, proteomics,
and other activities. The driving growth factor of PCR Based test is now a common and often
indispensable technique used in medical and biological research labs for a variety of
applications. These include DNA cloning for sequencing, DNA-based phylogeny, or functional
analysis of genes; the diagnosis of hereditary diseases; the identification of genetic
fingerprints (used in forensic sciences and paternity testing); and the detection and diagnosis
of infectious diseases.
21.996 21.89 21.85
17.97 17.74 17.18
11.44 11.98 12.31
16.51 18.71 20.814.74 4.46 4.129.11 8.46 8.2312.76 11.65 10.705.47 5.11 4.80
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2009 2010
Perc
ent
Food Pathogen Detection TestingNeurological Testing
Cardiovascular Disease Testing Tissue Typing Testing
Oncology Testing
Genetic Testing
Blood Screening Testing
Infectious Disease Testing
© Renub Research Page 16 of 27
Fish Testing Market is the fastest growing segment and projected to grow with 16.79% CAGR,
from 2010 to 2014. The market for FISH-based molecular diagnostic tools has been attractive
and will remain so in the foreseeable future. The vast majority of molecular diagnostic tests
rely on detection of nucleic acids and use of fluorescence, for sequencing and real-time
polymerase chain reaction (PCR), chemiluminescence for transcription-mediated
amplification, or a chromogenic method such as in situ hybridization. Fish & Innovation
testing is expected to capture 16.87% market share by 2014.
Figure 0-2: Global - Molecular Diagnostics Market Share Technologies wise (Percent), 2008 - 2010
Source: Jain PharmaBiotech, Renub Research Analysis
26.38 25.29 24.21
18.75 18.97 18.42
13.75 14.37 15.26
13.88 13.79 13.68
13.75 13.79 14.74
8.38 7.82 7.375.12 5.98 6.32
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2009 2010
Perc
ent
Other Technologies
Biosensor
Fish and Innovation
Non-PCR Tests
PCR Related Technologies
PCR Based Test
Biochips/Microarrays
© Renub Research Page 17 of 27
3 Molecular Diagnostics Market (Application Segment)
– 2008 to 2014
3.1 Infectious Disease Testing Market
An infectious disease is a clinically evident disease resulting from the presence of pathogenic
microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multi
cellular parasites, and aberrant proteins known as prions. The infectious disease testing
market is one of the most rapidly growing segments of the molecular diagnostics industry. The
continuous identification of new gene targets has enhanced the spectrum of disease profiles
for the molecular diagnostic market. However, the increasing incidences of human
immunodeficiency virus (HIV), hepatitis C (HCV), hepatitis B virus (HBV), chlamydia and
gonorrhea have escalated the infectious disease diagnostics segment to be a major
contributor to the revenue growth of the molecular diagnostics market.
Although, some infections are still a mystery, while for others the causative microorganisms
are present in minute concentrations long before the occurrence of first clinical symptoms,
recent advances in genetic engineering and detection technologies are creating exciting
opportunities for highly sensitive, specific and cost-effective products. With a high incidence
of infectious diseases in developing countries, the need for appropriate and early diagnosis of
these diseases is assuming greater importance. The high disease burden combined with
increasing focus from both, regional governments and global communities to treat these
diseases makes developing countries an attractive market for manufacturers of diagnostics for
infectious diseases. Increased international funding and government initiatives that are
expected to promote growth in the infectious disease diagnostics market.
But the major challenge in the markets is to develop diagnostic tests at affordable prices. The
plethora of diseases offers the researchers to develop novel biomarkers both for disease
identification and treatment. However, commercialization of these tests is a challenge, as
manufacturers will need to strike a balance between development costs and profit margins.
© Renub Research Page 18 of 27
Currently, the largest market application segment for molecular diagnostics is infectious
disease testing. The segment is expected to grow at an annual rate of 20.95 % between 2008
and 2014.Over the next few years it will present some excellent market opportunities for
molecular diagnostic competitors in the infectious disease market. The market was bullish
since 2008 with the sales of US$ 1,207 Million, the market further rose to US$ 1,592 Million in
2010 and it is predicted that the market will be clinching for the sales of US$ 3,778 Million by
2014.
Figure 3-1: Global - Forecast for Infectious Disease Testing Market (Million US$), 2011 - 2014
Source: Scientia Analysis, Kalorama, Frost & Sullivan, Company reports and presentations, Renub Research Analysis
1,895
2,318
2,917
3,778
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
2011 2012 2013 2014
Mill
ion
US$
© Renub Research Page 19 of 27
3.4 Oncology Testing Market
In addition to the infectious disease area, molecular diagnostics technology is now being
applied in a wide range of applications. Another major market segment consists of molecular
oncology tests. A significant challenge for diagnostics companies in developing molecular
diagnostics tests for cancer has been the identification and validation of biomarkers for
cancer, but progress is being made and tests are reaching the market.
Oncology tests can be used for many different indications, including identifying patients at
risk of developing cancer, screening for early detection of cancer, determining prognosis,
predicting response to therapy, and monitoring patients during and after treatment. The
oncology testing market were US$ 1,516 Million in 2010 and it is expected to reach US$ 4,249
Million by 2014 with the annual growth rate of 29.39% between 2007 and 2014.
Figure 3-2: Global - Forecast for Oncology Market (Million US$), 2011 - 2014
Source: TSG analysis, Qiagen, Roche, Hologic presentations, Renub Research Analysis
1,962
2,539
3,285
4,249
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2011 2012 2013 2014
Mill
ion
US$
© Renub Research Page 20 of 27
4 Molecular Diagnostics Market (Technologies
Segment) – 2008 to 2014
4.4 Fish & Innovations Testing Market (Fluorescent in-situ
hybridization)
A method of staining biological tissue samples to identify the presence and copy number of
specific genes or genetic mutations in cells; used in the diagnosis of cancer and other
diseases. The market for FISH-based molecular diagnostic tools has been attractive and will
remain so in the foreseeable future. The vast majority of molecular diagnostic tests rely on
detection of nucleic acids and use of fluorescence, for sequencing and real-time polymerase
chain reaction (PCR), chemiluminescence for transcription-mediated amplification, or a
chromogenic method such as in situ hybridization. The FISH testing market rose to US$ 1,400
Million in 2010 and it is predicted that market will reach to US$ 2,605 Million by 2014.
Figure 4-7: Global - Fish & Innovations Market (Million US$), 2005 - 2010
Source: Jain PharmaBiotech, Renub Research Analysis
850926
1,0091,100
1,200
1,400
0
200
400
600
800
1,000
1,200
1,400
1,600
2005 2006 2007 2008 2009 2010
Mill
ion
US$
© Renub Research Page 21 of 27
4.5 Biochips Market
The development of biochips is a major thrust for the rapidly growing biotechnology industry,
which encompasses a very diverse range of research efforts including genomics, proteomics,
and pharmaceuticals, among other activities. Advances in these areas are giving scientists
new methods for unraveling the complex biochemical processes occurring inside cells, with
the larger goal of understanding and treating human diseases. At the same time, the
semiconductor industry has been steadily perfecting the science of micro-miniaturization.
The merging of these two fields in recent years has enabled biotechnologists to begin packing
their traditionally bulky sensing tools into smaller and smaller spaces, onto so-called biochips.
These chips are essentially miniaturized laboratories that can perform hundreds or thousands
of simultaneous biochemical reactions. Biochips enable researchers to quickly screen large
numbers of biological analytic for a variety of purposes, from disease diagnosis to detection
of bioterrorism agents. The biochips market is booming with the advancement of the
technology. The biochips market rose to US$ 2,300 Million in 2010 and it is expected that
market will grow to US$ 3,742 Million by 2014.
Figure 4-1: Global - Forecast for Biochips/Micrroarrays Market (Million US$), 2011 - 2014
Source: Jain PharmaBiotech, Renub Research Analysis
2,450
3,000
3,4503,742
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
2011 2012 2013 2014
Mill
ion
US$
© Renub Research Page 22 of 27
5 Geographical Distribution - Molecular Diagnostics
Market (2008 to 2014)
5.1 United States Molecular Diagnostics Market
Molecular diagnostics segment is boon for the players who are doing the research as well as
manufacturing the product in United States. In recent years molecular diagnostics sector has
shown the phenomenal growth in the diagnostics segment. Due to rising demand for
diagnostics tests as population of baby boomers is aging in United States. The molecular
diagnostics market pegged to US$ 3,175 Million in 2010 and it is predicted that the market
will grow to US$ 6,138 Million by 2014. The infectious disease testing and blood-banking
applications will lead the way. Oncology diagnostics should post strong numbers in the years
to come due to rising cases of cancer patients in United States.
Figure 5-1: US - Molecular Diagnostics Market (Million US$), 2002 - 2010
Source: Frost & Sullivan
7941,032
1,1901,436
1,7462,063
2,381
2,778
3,175
0
500
1,000
1,500
2,000
2,500
3,000
3,500
2002 2003 2004 2005 2006 2007 2008 2009 2010
Mill
ion
US$
© Renub Research Page 23 of 27
5.2 Europe, the Middle East & Africa (EMEA) Molecular Diagnostics
Market
The need for early diagnosis of diseases and improved therapeutic treatment is driving the
adoption of molecular diagnostics tests in Europe, the Middle East & Africa (EMEA).
Automated and integrated molecular diagnostic solutions have improved assay performance
by decreasing the complexities involved in molecular tests. Although these solutions involve a
slightly higher cost, the inherent benefits, such as reduced labor and lower cost per assay are
promoting their uptake. With continued technological advances and expanding applications,
molecular diagnostics is one of the fastest growing areas in the EMEA In-Vitro Diagnostics
market.
Overall, the uptake of molecular diagnostic tests is gaining momentum as a result of the high
revenue potential in the infectious disease diagnostics market. Due to the presence of
multinational companies and their dominance, the infectious disease diagnostics market is
expected to offer limited opportunities to new entrants. Hence, companies would do well to
be aware of the trends in the oncology diagnostics and genetic tests segments, which are
currently in their growth phase and offer enormous scope for market expansion. The
molecular diagnostics is poised to do better in the market, with market rose US$ 1,025 Million
in 2010 and it is predicted that the market will reach US$ 1,882 Million by 2014.
© Renub Research Page 24 of 27
Figure 5-1: EMEA - Forecast for Molecular Diagnostics Market (Million US$), 2011 - 2014
Source: Roche Analysis, Company Reports, Boston Biomedical Consultants, Renub Research Analysis
1,1931,389
1,617
1,882
0200400600800
1,0001,2001,4001,6001,8002,000
2011 2012 2013 2014
Mill
ion
US$
© Renub Research Page 25 of 27
Related Reports
Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs
Analysis
Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
Personalized Medicine Market (2010 - 2015) - By Segments, Technologies, Opportunities,
Challenges & Future Forecast
World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
Glucose Monitoring Devices Market Worldwide (2010 – 2014)
Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin,
DPP-IV, GLP-1
Asia Medical Tourism Analysis (2008 – 2013)
Global Molecular Diagnostics Market: Opportunities & Future Forecast
© Renub Research Page 26 of 27
Our Partial List of Clients
Bain
WAKE Technology Services, Inc.
PSS World Medical
Relypsa
C&K components
Konkuk University
Resonetics
Samsung
SEKISUI MEDICAL CO. LTD.
Plentyoffish Media INC
Arthur D Little Gmbh
Morgan Stanley
Takeda Pharmaceutical Corporation
Hokkai School of Commerce
Ministry of Manpower Singapore
GenOmind, LLC.
Goldman Sachs & Co
NTT Advanced Technology
Tokyo Womens Medical University
The Chemo-Sero-Therapeutic Research
Trade Council of Iceland
Jpmorgan, Ets Trading
GE Healthcare IT
Redbus
Becton Dickinson
Pfizer
Intercell
Sanofi Pasteur
Stanford Burgess
Pequot Capital
DMI
Transgene S.A.
ixia communications
Toyota Tsusho Amercia Inc.
National Health Research Institutes
Abbott Diabetes Care
Corning Incorporated - Life Sciences
L.E.K. Consulting GmbH
Syntiron
MediVas LLC
Credit Suisse
Dune Medical
QIAGEN
Inje University
Mapp Biopharmaceutical
Institute for Information Industry
© Renub Research Page 27 of 27
Disclaimer
This research report is published by Renub Research. All rights reserved. Reproduction or
redistribution of this research report in any form for any business purpose is expressly
prohibited without written permission of www.renub.com and any payments of a specified
fee. Requests to republish any material may be sent to us at [email protected].
Most of the information available in this report is within the public domain. The submitting
authors or other copyright holders retain rights for reproduction or redistribution. All persons
reproducing or redistributing this information are expected to adhere to the terms and
constraints invoked by the copyright holder. Such protected material, however, may be used
under the terms of "fair use” as defined in the copyright laws, which generally permit use for
non-commercial educational purposes such as teaching, research, criticism, and news
reporting.
With respect to documents available, neither the company nor any of its employees makes
any warranty, express or implied, including the warranties of merchantability and fitness for
a particular purpose, or assumes any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, apparatus, product, or process disclosed, or
represents that its use would not infringe privately owned rights.
